Free Access
Issue
Med Sci (Paris)
Volume 28, Number 1, Janvier 2012
Page(s) 11 - 13
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2012281003
Published online 27 January 2012
  1. Amigorena S, Bonnerot C, Drake JR, et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 1992 ; 256 : 1808–1812. [CrossRef] [PubMed] [Google Scholar]
  2. Amigorena S, Salamero J, Davoust J, Fridman WH, Bonnerot C. Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature 1992 ; 358 : 337–341. [CrossRef] [PubMed] [Google Scholar]
  3. Daëron M, Latour S, Malbec O, et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995 ; 3 : 635–646. [CrossRef] [PubMed] [Google Scholar]
  4. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000 ; 6 : 443–446. [CrossRef] [PubMed] [Google Scholar]
  5. Li F, Ravetch JV. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 2011 ; 333 : 1030–1034. [CrossRef] [PubMed] [Google Scholar]
  6. Les anticorps monoclonaux en thérapeutique. Med Sci (Paris) 2009 ; 25 : 997–1195 (numéro thématique). [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Zitvogel L, Amigorena S, Teillaud JL. À propos de Ralph Steinman et des cellules dendritiques. Med Sci (Paris) 2011 ; 27 : 1028–1034. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  8. White AL, Chan HT, Roghanian A, et al. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 2011 ; 187 : 1754–1763. [CrossRef] [PubMed] [Google Scholar]
  9. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 1998 ; 95 : 652–656. [CrossRef] [Google Scholar]
  10. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002 ; 195 : 1653–1659. [CrossRef] [PubMed] [Google Scholar]
  11. Abes R, Gélizé E, Fridman WH, Teillaud JL. Long-lasting anti-tumor protection by anti-CD20 antibody through cellular immune response. Blood 2010 ; 116 : 926–934. [CrossRef] [PubMed] [Google Scholar]
  12. Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010 ; 18 : 160–170. [CrossRef] [PubMed] [Google Scholar]
  13. Abes R, Dutertre CA, Teillaud JL. Les anticorps : mieux les connaître pour mieux s’en servir. Med Sci (Paris) 2009 ; 27 : 1011–1020. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  14. Abes R. Induction de réponses immunes anti-tumorales in vivo à la suite du traitement par anticorps anti-CD20 : existence d’un effet « vaccinal » des anticorps anti-tumoraux ? École doctorale B2M-biochimie et biologie moléculaire. Thèse de Doctorat de l’université Paris 6-Pierre et Marie Curie, 2010. [Google Scholar]
  15. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008 ; 8 : 34–47. [CrossRef] [PubMed] [Google Scholar]
  16. Tedder TF, Baras A, Xiu Y. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Semin Immunopathol 2006 ; 28 : 351–364. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.